Results 141 to 150 of about 2,705 (182)

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal. [PDF]

Hum Vaccin Immunother, 2023
Chaudhary S, Shah GS, Bhatta NK, Poudel P, Rai B, Uranw S, Tripathi PM, Khanal B, Ghimire A, Rai N, Gupta BP, Vemula S, Wartel TA, Sahastrabuddhe S, Saluja T.   +14 more
europepmc   +1 more source

Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe. [PDF]

Vaccine, 2022
Shaum A, Mujuru HA, Takamiya M, Ticklay I, Nathoo K, Sreenivasan N, Nyambayo P, Chitando P, Marembo J, Koline Chigodo C, Mukaratirwa A, Jacha V, Gidudu JF, Rupfutse M, Kumar Jain S, Manangazira P, Bennett SD.   +16 more
europepmc   +1 more source

Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi. [PDF]

Vaccine X
Debellut F, Bello G, Chisema M, Mkisi R, Kamzati M, Pecenka C, Mugisha E.   +6 more
europepmc   +1 more source

Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study. [PDF]

J Infect Dis, 2021
Ryckman T, Karthikeyan AS, Kumar D, Cao Y, Kang G, Goldhaber-Fiebert JD, John J, Lo NC, Andrews JR.   +8 more
europepmc   +1 more source

Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign. [PDF]

Am J Trop Med Hyg
Date K, LeBoa C, Hoffman SA, Haldar P, Harvey P, An Q, Zhang C, Yewale VN, Daruwalla S, Dharmapalan D, Gavhane J, Joshi S, Rai R, Rathod V, Shetty K, Warrier DS, Yadav S, Shimpi R, Jayaprasad N, Horng L, Fagerli K, Borhade P, Chakraborty D, Katkar A, Kunwar A, Andrews JR, Bahl S, Bhatnagar P, Dutta S, Luby SP.   +29 more
europepmc   +1 more source

Development status of typhoid conjugate vaccines globally [PDF]

International Journal of Infectious Diseases, 2016
openaire   +1 more source

Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV^Ⓡ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study. [PDF]

IJID Reg
Thuluva S, Matur RV, Gunneri S, Mogulla R, Dhar C, Yerroju V, Balne N, Chakravarthy BS, Narang M, Mahantshetti NS, Pandey AK.   +10 more
europepmc   +1 more source

Factors Influencing Vaccine Receipt During a 2018 Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India. [PDF]

Am J Trop Med Hyg
Borhade P, LeBoa C, Jayaprasad N, Date K, Haldar P, Harvey P, Shimpi R, An Q, Zhang C, Horng L, Fagerli K, Yewale VN, Daruwalla S, Dharmapalan D, Gavhane J, Joshi S, Rai R, Rathod V, Shetty K, Warrier DS, Yadav S, Chakraborty D, Bahl S, Katkar A, Kunwar A, Andrews JR, Bhatnagar P, Dutta S, Luby SP, Hoffman SA.   +29 more
europepmc   +1 more source

Typhoid conjugate vaccine gets WHO prequalification [PDF]

The Lancet Infectious Diseases, 2018
openaire   +1 more source

Safety and Immunogenicity of a Bivalent Paratyphoid A-Typhoid Conjugate Vaccine in Healthy Indian Adults: A Phase I, Randomized, Active Controlled Study

, 2023
Kulkarni PS, Potey AV, Bharati S, Kunhihitlu A, Narasimha B, Sindhu Y, Dharmadhikari A, Gavade V, Kamat CD, Mallya AD, Sarma AD, Goel S, Pisal SS, Poonawalla C, Venkatesan R, Jones E, Flaxman A, Kim YC, Pollard AJ, Group TS.   +19 more
europepmc   +1 more source